Jonathan B Bricker1, Wade Copeland2, Kristin E Mull2, Emily Y Zeng2, Noreen L Watson2, Katrina J Akioka2, Jaimee L Heffner2. 1. Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, 1100 Fairview Avenue N., Seattle, WA 98109, USA; University of Washington, Department of Psychology, Box 351525, Seattle, WA 98195, USA. Electronic address: jbricker@fhcrc.org. 2. Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, 1100 Fairview Avenue N., Seattle, WA 98109, USA.
Abstract
BACKGROUND: The first randomized trial of a smartphone application (app) for adult smoking cessation (SmartQuit 1.0) revealed key features that predict cessation. These findings guided the revision of this Acceptance & Commitment Therapy (ACT)-based application (SmartQuit 2.0), which was primarily tested to examine participant receptivity, short-term cessation and reduction, and the relationship between program completion, smoking cessation and reduction. Secondarily, outcomes were descriptively compared with the SmartQuit1.0 trial. METHOD:Adult participants (78% female, 25% with high school or less education, 30% unemployed) were recruited into the single-arm pilot trial (N=99) of SmartQuit 2.0 with a two-month follow-up (85% retention). RESULTS: Regarding receptivity, 84% of participants were satisfied with SmartQuit 2.0 (vs. 59% for SmartQuit1.0), 73% would recommend it to a friend (vs. 48% for SmartQuit1.0), 81% found the ACT exercises useful for quitting (vs. 44% for SmartQuit1.0). At the 2-month follow-up, the quit rates were 21% for 7-day point prevalence (vs. 23% for SmartQuit1.0), 11% for 30-day point prevalence (vs. 13% for SmartQuit1.0), and 75% of participants reduced their smoking frequency (vs. 57% for SmartQuit1.0). Among program completers (24% of total sample), the quit rates were 33% for 7-day point prevalence, 28% for 30-day point prevalence, and 88% of participants reduced their smoking frequency. CONCLUSIONS: The revised app had high user receptivity, modest quit rates, and high smoking reduction rates. Program completion may be key to boosting the app's effectiveness.
RCT Entities:
BACKGROUND: The first randomized trial of a smartphone application (app) for adult smoking cessation (SmartQuit 1.0) revealed key features that predict cessation. These findings guided the revision of this Acceptance & Commitment Therapy (ACT)-based application (SmartQuit 2.0), which was primarily tested to examine participant receptivity, short-term cessation and reduction, and the relationship between program completion, smoking cessation and reduction. Secondarily, outcomes were descriptively compared with the SmartQuit1.0 trial. METHOD: Adult participants (78% female, 25% with high school or less education, 30% unemployed) were recruited into the single-arm pilot trial (N=99) of SmartQuit 2.0 with a two-month follow-up (85% retention). RESULTS: Regarding receptivity, 84% of participants were satisfied with SmartQuit 2.0 (vs. 59% for SmartQuit1.0), 73% would recommend it to a friend (vs. 48% for SmartQuit1.0), 81% found the ACT exercises useful for quitting (vs. 44% for SmartQuit1.0). At the 2-month follow-up, the quit rates were 21% for 7-day point prevalence (vs. 23% for SmartQuit1.0), 11% for 30-day point prevalence (vs. 13% for SmartQuit1.0), and 75% of participants reduced their smoking frequency (vs. 57% for SmartQuit1.0). Among program completers (24% of total sample), the quit rates were 33% for 7-day point prevalence, 28% for 30-day point prevalence, and 88% of participants reduced their smoking frequency. CONCLUSIONS: The revised app had high user receptivity, modest quit rates, and high smoking reduction rates. Program completion may be key to boosting the app's effectiveness.
Authors: Jack F Hollis; Timothy A McAfee; Jeffrey L Fellows; Susan M Zbikowski; Michael Stark; Karen Riedlinger Journal: Tob Control Date: 2007-12 Impact factor: 7.552
Authors: David B Buller; Ron Borland; Erwin P Bettinghaus; James H Shane; Donald E Zimmerman Journal: Telemed J E Health Date: 2013-12-18 Impact factor: 3.536
Authors: Daniel Westreich; Stephen R Cole; Michele Jonsson Funk; M Alan Brookhart; Til Stürmer Journal: Pharmacoepidemiol Drug Saf Date: 2010-12-09 Impact factor: 2.890
Authors: Scott J Leischow; Keith Provan; Jonathan Beagles; Joseph Bonito; Erin Ruppel; Gregg Moor; Jessie Saul Journal: Am J Public Health Date: 2012-09-20 Impact factor: 9.308
Authors: Jonathan B Bricker; Kristin E Mull; Julie A Kientz; Roger Vilardaga; Laina D Mercer; Katrina J Akioka; Jaimee L Heffner Journal: Drug Alcohol Depend Date: 2014-07-17 Impact factor: 4.492
Authors: Ryan J Courtney; Philip Clare; Veronica Boland; Kristy A Martire; Billie Bonevski; Wayne Hall; Mohammad Siahpush; Ron Borland; Christopher M Doran; Robert West; Michael Farrell; Richard P Mattick Journal: Addict Behav Date: 2016-08-02 Impact factor: 3.913
Authors: Melvyn W B Zhang; Bach Xuan Tran; Huong Lan Thi Nguyen; Huong Thi Le; Nguyen Hoang Long; Huong Thi Le; Nguyen Duc Hinh; Tran Dinh Tho; Bao Nguyen Le; Vu Thi Minh Thuc; Chau Ngo; Nguyen Huu Tu; Carl A Latkin; Roger Cm Ho Journal: Healthc Inform Res Date: 2017-04-30
Authors: Roger Vilardaga; Javier Rizo; Emily Zeng; Julie A Kientz; Richard Ries; Chad Otis; Kayla Hernandez Journal: JMIR Serious Games Date: 2018-01-16 Impact factor: 4.143
Authors: Chris A Schmidt; James K Romine; Melanie L Bell; Julie Armin; Judith S Gordon Journal: JMIR Mhealth Uhealth Date: 2017-10-09 Impact factor: 4.773